Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CCND3 | P30281 | 1/20 | 0.31 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30309543 | 1.00 | TRPV4 (0.34) | TRPV4ALDH1A1GAATDP1CCND3 | |
| SCHEMBL23978127 | 0.87 | TRPV4 (0.35) | TRPV4ALDH1A1GAATDP1CCND3 | |
| SCHEMBL30309532 | 0.87 | TRPV4 (0.35) | TRPV4ALDH1A1GAATDP1CCND3 | |
| SCHEMBL23978116 | 0.87 | TRPV4 (0.38) | TRPV4ALDH1A1GAATDP1CCND3 | |
| SCHEMBL30309547 | 0.87 | TRPV4 (0.38) | TRPV4ALDH1A1GAATDP1CCND3 | |
| SCHEMBL23978358 | 0.76 | LCK (0.41) | ALDH1A1TDP1CCND3CDK6 | |
| SCHEMBL30309599 | 0.76 | LCK (0.41) | ALDH1A1TDP1CCND3CDK6 | |
| SCHEMBL23978095 | 0.76 | — | — | |
| SCHEMBL23978363 | 0.76 | CYP1A2 (0.39) | TRPV4ALDH1A1CCND3CDK6 | |
| SCHEMBL23978179 | 0.76 | CCND3 (0.36) | TRPV4ALDH1A1CCND3CDK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2023-06-22 | — | — | US | disclosed |
| WO-2021219731-A2 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192701-A1 | BICYCLIC KINASE INHIBITORS AND USES THEREOF | MITF, PRKDC, PRKACA | TRPV4 3730/4885ALDH1A1 3047/4885GAA 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.